THE NEXT FRONTIER IN PET HEALTH IS METABOLIC SIGNALING

PETNUTRA is bringing human-tested GLP-1 science into pet nutrition

G-Loop™ is PETNUTRA's first product, a daily supplement for dogs developed around clinically tested ERIOMIN®, a citrus bioflavonoid complex. The company holds the exclusive rights to bring ERIOMIN® beyond human health, beginning with dogs.



WHY NOW

We look after our own metabolic health. What about our dogs'?

Dog care hasn't caught up. Most of it still waits for a symptom, then treats that one problem. GLP-1 is one of the body's key metabolic signals, and every dog makes it in the gut.*

An NIH-funded 2026 study found the GLP-1 drug semaglutide extended median lifespan in older female mice by nearly 100 days.[1] Research on GLP-1 drugs has linked GLP-1 signaling to as many as nine of the 12 hallmarks of aging. U.S. pet spending hit $158 billion in 2025; 71 million households have a dog and 53 million a cat.[2] Diabetes is common in cats.[3]

THE PROOF

ERIOMIN® raised GLP-1 in three human trials

+15.6%
2019 · *Phytother. Res.*

+17%
2022 · *J. Med. Food*

+22%
2023 · *Food Sci. Nutr.*

Each was a 12-week randomized, double-blind, placebo-controlled trial in adults. Results shown are for 200 mg of ERIOMIN® a day; placebo groups showed little or no change.[4] Dogs make GLP-1 too, and canine studies are designed and ready for this raise to fund.

THE ADVANTAGE

Exclusive ERIOMIN® rights give PETNUTRA a head start in pet metabolic health

Patented science
Three U.S. patents cover ERIOMIN®: Nos. 10,596,185, 11,197,879, and 11,197,880.

From ERIOMIN®'s makers
Rob Brewster co-founded Ingredients by Nature, maker of ERIOMIN®. His family's lab has worked on these molecules since 1932.

In members' homes
PETNUTRA has developed and packaged G-Loop™, and the first Inner Circle families brought it home in 2026.

THE PRODUCT

G-Loop™ turns metabolic science into a daily ritual

Daily simplicity
One stick pack at mealtime, once a day, with 30 to a box.

Cats come next
The Small formula already fits cats, a second large market.

Built for repeat purchase
A daily product launching direct to consumer in Q2 2027.

G-Loop™ does not contain GLP-1 and is not a GLP-1 agonist drug or a weight loss supplement.

AT A GLANCE

Company	Pet Nutraceuticals, Inc. (PETNUTRA)
Founded	2022
Office	Whitefish, Montana
Product	G-Loop™, a daily supplement for dogs
Stage	Pre-launch, with a waitlist open
Raising	$3M
Launch	Q2 2027, direct to consumer
Next	Cats, same formula as Small

EARLY VALIDATION

Top 10 finalist, 2026 Pet Care Innovation Prize.

Finalist, 2026 LEAP Venture Studio.

The Inner Circle. It's an application-only membership with a cap on spots. Founding Members try G-Loop™ with their dogs for 60 days before launch.

TEAM

Rob Brewster, Founder and CEO
Shanan Carney, Co-Founder, CBO
Darren Lancaster, Co-Founder, CMO
Eddie Gershman, Co-Founder, VP Sales

Advisors: Doug Lynch; Dr. Bart Dunsford, PhD, PAS (formulation); Dr. Stephanie Lipp, DVM.



THE RAISE

$3M to launch G-Loop™, fund canine studies, and build recurring revenue.

Checks to $500K	SAFE note, $15M cap, 15% discount
Over $500K	Equity round, valuation negotiated
To date	$400K raised since inception

Use of funds

Customer acquisition 30%, inventory and manufacturing 25%, product development 20%, operations and admin 15%, and clinical studies 10%.

Rob Brewster, Founder and CEO · rob@petnutra.com · (833) 258-8738

*These statements have not been evaluated by the Food and Drug Administration. G-Loop™ is not intended to diagnose, treat, cure, or prevent any disease.

[1] Feng et al., *Nature*, 2026. [2] APPA, 2026. [3] *Merck Vet Manual*, 2026. [4] doi.org/10.1002/ptr.6386 · doi.org/10.1089/jmf.2021.0181 · doi.org/10.1002/fsn3.3654. ERIOMIN® and BLUSSEL® are registered trademarks.